Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
Ramesh K. Ramanathan, Donald L. Trump, Julie L. Eiseman, Chandra P. Belani, Sanjiv S. Agarwala, Eleanor G. Zuhowski, Jing Lan, Douglas M. Potter, S. Percy Ivy, Sakkaraiappan Ramalingam, Adam M. Brufsky, Michael K.K. Wong, Susan Tutchko, Merrill J. Egorin
Dive into the research topics of 'Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers'. Together they form a unique fingerprint.